<DOC>
	<DOCNO>NCT00920023</DOCNO>
	<brief_summary>The purpose research study see specific kind MRI , call Ultrasmall Superparamagnetic Iron Oxide Magnetic Resonance Imaging ( USPIO MRI ) , use FDA-approved therapeutic agent ( Feraheme ) see able identify small otherwise undetectable lymph node metastases people pancreatic cancer schedule surgical resection .</brief_summary>
	<brief_title>Pre-Operative Staging Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging ( SPIO MRI )</brief_title>
	<detailed_description>- On first day , study participant undergo 2 MRI examination . A scan do prior administration contrast agent ( Feraheme ) second scan immediately administration . On second day , study participant ask return third MRI . - All MRI scan do Massachusetts General Hospital .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Dextrans</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Locally resectable pancreatic mass present one preoperative imaging modality Must demonstrate evidence distant metastasis assess chest/abdomen/pelvis CT scan Deemed eligible resection curative intent treat surgeon list investigator study 18 year age old No uncontrolled serious medical psychiatric illness Women childbearing potential must pregnant lactate Known allergy iron dextran Pregnant lactate Counterindication MRI , presence metallic prosthesis implant metal device Sickle cell disease hemoglobinopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>SPIO MRI</keyword>
	<keyword>Feridex</keyword>
</DOC>